TCRX

Tscan Therapeutics Inc

0.3915

Sep 04 • 3:59 PM ET +0.0206 (5.55%)

0.3914

Aftermarket • 7:50 PM ET -0.0001 (-0.03%)

Healthcare Biotechnology USA Nano NASD

Peers: ANVS EXOZ FBIO MCRB PLRX PMVP RLYB XBIT ICCC QTTB

| Held by: VTI VXF IWC BUSM

Scroll to Statements

Index	-
Market Cap	26.54M
Enterprise Value	17.27M
Income	-117.71M
Sales	7.11M
Book/sh	1.02
Cash/sh	1.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	142
IPO	Jul 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	3.73
P/B	0.38
P/C	0.26
P/FCF	-
EV/EBITDA	-
EV/Sales	2.43
Quick Ratio	3.37
Current Ratio	3.37
Debt/Eq	1.32
LT Debt/Eq	1.04
Option/Short	No / Yes

EPS (ttm)	-0.91
EPS next Y	-0.83
EPS next Q	-0.28
EPS this Y	-5.85%
EPS next Y	21.39%
EPS next 5Y	6.78%
EPS past 3/5Y	28.66% 2.08%
Sales past 3/5Y	-8.63% 56.92%
EPS Y/Y TTM	17.34%
Sales Y/Y TTM	2.15%
EPS Q/Q	17.98%
Sales Q/Q	-65.83%
Earnings	Aug 12 BMO
EPS/Sales Surpr.	9.23% -43.95%

Insider Own	14.64%
Insider Trans	0.00%
Inst Own	50.36%
Inst Trans	30.63%
ROA	-50.09%
ROE	-95.80%
ROIC	-83.79%
Gross Margin	59.47%
Oper. Margin	-1695.15%
Profit Margin	-1655.35%
SMA20	-44.84%
SMA50	-52.79%
SMA200	-60.82%
Trades

Shs Outstand	63.50M
Shs Float	57.86M
Short Float	2.77%
Short Ratio	2.11
Short Interest	1.60M
52W High	2.57 -84.77%
52W Low	0.35 11.67%
Volatility	22.20% 9.27%
ATR (14)	0.07
RSI (14)	20.27
Beta	1.09
Rel Volume	2.21
Avg Volume	759.24K
Volume	1,674,586

Perf Week	-48.04%
Perf Month	-48.70%
Perf Quarter	-60.13%
Perf Half Y	-65.04%
Perf YTD	-60.85%
Perf Year	-79.29%
Perf 3Y	-84.09%
Perf 5Y	-95.40%
Perf 10Y	-
Recom	2.33
Target Price	4.67
Prev Close	0.37
Price	0.39
Change %	5.55%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-16-24	Initiated	BTIG Research	Buy	$12
May-13-24	Initiated	Needham	Buy	$11
Jun-22-23	Initiated	Wedbush	Outperform	$8

Sep-04-26 05:00AM	Ionis rare neurology drug approved; Pfizer inks an ADC deal (BioPharma Dive) +5.55%
Sep-02-26 08:30AM	TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program (InvestorsHub) -42.80%
07:00AM	TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors (GlobeNewswire)
Aug-12-26 07:00AM	TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-26 06:17AM	Cell and gene therapy manufacturers turn to specialist automation partners (Pharmaceutical Technology)
07:00AM	Loading…
Jul-29-26 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies (GlobeNewswire)
Jun-24-26 07:00AM	TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference (GlobeNewswire)
Jun-22-26 07:00AM	TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation (GlobeNewswire) -5.97%
Jun-03-26 09:19AM	Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies (Business Wire)
May-06-26 07:00AM	TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-27-26 04:30PM	TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting (GlobeNewswire)
Apr-08-26 07:00AM	TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-26 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-26 07:00AM	TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 (GlobeNewswire)
12:15PM	Loading…
Feb-25-26 12:15PM	Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +5.71%
07:00AM	TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-12-26 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-11-26 07:25AM	Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? (Zacks)
Feb-06-26 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +13.14%
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
Dec-06-25 05:30PM	TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire) +6.86%
Dec-03-25 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities (GlobeNewswire) +7.12%
Nov-12-25 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-25 05:10PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +11.93%
Nov-06-25 09:15AM	Novavax (NVAX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-05-25 08:20AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
06:30AM	Loading…
Nov-03-25 06:30AM	TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 (GlobeNewswire) -36.08%
Oct-30-25 09:15AM	Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-16-25 07:30AM	2 Overlooked Stocks to Snap Up in 2025 (Barchart) +11.21%
Sep-17-25 07:00AM	TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 (GlobeNewswire) -6.98%
Sep-03-25 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.86%
Aug-12-25 03:00PM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-04-25 08:25AM	Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.56%
May-28-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-06-25 08:20AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-25 04:53PM	TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting (GlobeNewswire)
Mar-31-25 07:00AM	TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 07:00AM	TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access (GlobeNewswire)
Mar-05-25 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.76%
Feb-18-25 07:00AM	TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Jan-10-25 09:35AM	Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks (Zacks)
Dec-26-24 07:00AM	TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium (GlobeNewswire) +6.87%
Dec-23-24 07:00AM	TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank (GlobeNewswire)
Dec-09-24 05:45PM	TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) -28.23%
Dec-05-24 08:00AM	TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years (GlobeNewswire) -5.39%
Dec-02-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Heme Development Strategy (GlobeNewswire)
Nov-12-24 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:43AM	TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? (Zacks)
Nov-05-24 09:15AM	TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-04-24 09:05AM	TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting (GlobeNewswire)
Aug-29-24 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-14-24 07:00AM	TScan Therapeutics Announces Updates to its Board of Directors (GlobeNewswire) -6.67%
May-30-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies (GlobeNewswire) -6.41%
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-13-24 01:53PM	TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:09AM	Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target (MT Newswires)
07:00AM	TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors (GlobeNewswire)
May-01-24 10:01AM	TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +11.66%
Apr-24-24 04:05PM	TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
11:03AM	TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-22-24 05:01PM	TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Apr-19-24 10:05AM	TScan Therapeutics Announces Closing of Upsized Public Offering (GlobeNewswire)
Apr-17-24 12:30AM	TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering (GlobeNewswire) -5.33%
Apr-16-24 04:25PM	TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering (GlobeNewswire) -7.28%
04:01PM	TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities (GlobeNewswire)
Apr-08-24 08:00AM	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer (GlobeNewswire)
Apr-02-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.11%
Mar-17-24 02:58PM	Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With (InvestorPlace)
Mar-07-24 01:44PM	TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline (GuruFocus.com)
Mar-06-24 01:51PM	TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-26-24 07:00AM	TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-19-24 05:49AM	TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar? (Zacks)
Feb-14-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-06-24 07:00AM	TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development (GlobeNewswire) +6.67%
Jan-29-24 07:00AM	TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer (GlobeNewswire)
Jan-18-24 07:00AM	TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire) -9.62%
Jan-04-24 07:00AM	TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-09-23 12:00PM	TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-07-23 07:00AM	TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations (GlobeNewswire)
Dec-06-23 08:50AM	Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why (Zacks)

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Waltham, MA.

PhDGavin MacBeath

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Dec 19 '25	Buy	0.90	80,069	71,974	7,937,416	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	Dec 22 '25	Buy	0.90	75,500	67,950	8,012,916	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	Dec 23 '25	Buy	0.90	6,232	5,602	8,019,148	Dec 23 06:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRX

Tscan Therapeutics Inc

Upgrade your Finviz experience